Novo Nordisk A/S $NVO Shares Bought by Martin Capital Partners LLC

Key Points

• Martin Capital Partners LLC significantly increased its holdings in Novo Nordisk A/S by 261.5% in the second quarter, owning 76,448 shares worth approximately $5.28 million.
• Recent analyst activities include upgrades from Sanford C. Bernstein to "outperform," while HSBC and others lowered their ratings, indicating mixed market sentiment towards Novo Nordisk shares.
• Novo Nordisk reported earnings of $0.97 per share for the last quarter, exceeding analyst expectations, and announced a dividend of $0.4119 with a payout ratio of 22.53%.

Martin Capital Partners LLC raised its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 261.5% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 76,448 shares of the company's stock after purchasing an additional 55,298 shares during the quarter. Novo Nordisk A/S comprises approximately 2.1% of Martin Capital Partners LLC's investment portfolio, making the stock its 24th biggest holding. Martin Capital Partners LLC's holdings in Novo Nordisk A/S were worth $5,276,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Copeland Capital Management LLC increased its stake in shares of Novo Nordisk A/S by 184.8% in the first quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock valued at $27,000 after purchasing an additional 255 shares during the period. North Capital Inc. acquired a new position in shares of Novo Nordisk A/S during the first quarter valued at approximately $27,000. Park Square Financial Group LLC acquired a new position in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $29,000. Stone House Investment Management LLC acquired a new position in shares of Novo Nordisk A/S during the first quarter valued at approximately $30,000. Finally, Disciplina Capital Management LLC increased its stake in shares of Novo Nordisk A/S by 162.3% during the first quarter. Disciplina Capital Management LLC now owns 480 shares of the company's stock valued at $33,000 after acquiring an additional 297 shares during the period. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Trading Up 1.2%

Shares of NYSE:NVO opened at $54.94 on Monday. The firm has a fifty day moving average of $57.96 and a two-hundred day moving average of $66.17. The firm has a market capitalization of $245.31 billion, a P/E ratio of 15.09, a price-to-earnings-growth ratio of 2.08 and a beta of 0.66. Novo Nordisk A/S has a 12-month low of $45.05 and a 12-month high of $138.22. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.93 by $0.04. The company had revenue of $11.69 billion during the quarter, compared to analyst estimates of $77.51 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. On average, equities analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Investors of record on Monday, August 18th were issued a $0.4119 dividend. This represents a yield of 240.0%. The ex-dividend date was Monday, August 18th. Novo Nordisk A/S's dividend payout ratio (DPR) is 22.53%.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from a "market perform" rating to an "outperform" rating in a research note on Tuesday, September 9th. HSBC lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 price objective on the stock. in a research note on Thursday, July 31st. Wall Street Zen lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Barclays restated an "equal weight" rating on shares of Novo Nordisk A/S in a research report on Wednesday, July 30th. Finally, BNP Paribas upgraded shares of Novo Nordisk A/S from an "underperform" rating to a "neutral" rating in a research report on Wednesday, August 13th. Four investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $81.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.